A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases
Atherosclerosis, ISSN: 0021-9150, Vol: 322, Page: 31-38
2021
- 17Citations
- 21Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef7
- Captures21
- Readers21
- 21
Article Description
GPIHBP1 is an accessory protein of lipoprotein lipase (LPL) essential for its functioning. Mutations in the GPIHBP1 gene cause a deficit in the action of LPL, leading to severe hypertriglyceridemia and increased risk for acute pancreatitis. We describe twelve patients (nine women) with a novel homozygous mutation in intron 2 of the GPIHBP1 gene. All patients were from the Northeastern region of Brazil and presented the same homozygous variant located in a highly conserved 3′ splicing acceptor site of the GPIHBP1 gene. This new variant was named c.182-1G > T, according to HGVS recommendations. We verified this new GPIHBP1 variant's effect by using the Human Splicing Finder (HSF) tool. This mutation changes the GPIHBP1 pre-mRNA processing and possibly causes the skipping of the exon 3 of the GPIHBP1 gene, affecting almost 50% of the cysteine-rich Lys6 GPIHBP1 domain. Patients presented with severe hypertriglyceridemia (2351 mg/dl [885–20600]) and low HDL (18 mg/dl [5–41). Four patients (33%) had a previous history of acute pancreatitis. We describe a novel GPIHBP1 pathogenic intronic mutation of patients from the Northeast region of Brazil, suggesting the occurrence of a founder effect.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0021915021000927; http://dx.doi.org/10.1016/j.atherosclerosis.2021.02.020; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85102035064&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33706081; https://linkinghub.elsevier.com/retrieve/pii/S0021915021000927; https://dx.doi.org/10.1016/j.atherosclerosis.2021.02.020
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know